No abstract

In Africa, 8% of leprosy patients have the lepromatous form, and 85% have the tuberculoid form of the disease. Treating these patients with dapsone needs severa] years to produce good results, treatment with acedapsone is still in the experimental st age, and rifampicin is too expensive. There are two drugs remaining; clofazimine, which is the treatment of choice for those with lepromatous leprosy, and sulphanilamides, treatment for the tuberculoid form of leprosy and for acute inflammation af the peripheral nerves.

No abstract